COVID-19 vaccine effectiveness
(Randomized evidence)

If you want to see all comparisons, please click here

BNT162b2 primed with ChAdOx1-S vs No vaccine

You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.

Forest plots
(last update: 2021-07-15)

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04860739, EudraCT2021-001978-37
Pfizer/BioNTech + Fosun Pharma
Borobia A M, Lancet, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

No vaccine

RCT
Phase 2
Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain. N=676
Some concerns
Details

Full description